Where Pharmaceutical Companies are Heading: Complementary Research on Covance, Intrexon, Quintiles Transnational, NanoViricides, and Aradigm
NEW YORK, February 26, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Covance (NYSE: CVD), Intrexon (NYSE: XON), Quintiles Transnational (NYSE: Q), NanoViricides (NYSEMKT: NNVC), and Aradigm (NASDAQ: ARDM). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CVD Research Report: ( http://get.analystsreview.com/pdf/?c=Covance&d=26-Feb-2015&s=CVD ),
XON Research Report: ( http://get.analystsreview.com/pdf/?c=Intrexon&d=26-Feb-2015&s=XON ),
Q Research Report: ( http://get.analystsreview.com/pdf/?c=Quintiles%20Transnational&d=26-Feb-2015&s=Q ),
NNVC Research Report: ( http://get.analystsreview.com/pdf/?c=NanoViricides&d=26-Feb-2015&s=NNVC ),
ARDM Research Report: ( http://get.analystsreview.com/pdf/?c=Aradigm&d=26-Feb-2015&s=ARDM ).
============
--
Analyst Update: Agreements, Study Results, and Patent Grants
Reviewed by: Rohit Tuli, CFA®
U.S. stock markets witnessed a mixed trend on Wednesday as the Dow inched further into record territory but the Nasdaq broke its 10-day winning streak. The Dow Jones Industrial Average rose 15.38 points, or 0.08%, to 18224.57. The S&P 500 lost 1.62 points to 2113.86, while the Nasdaq Composite declined 0.98 points, or 0.02%, to 4967.14. Trading was relatively subdued ahead of the release of economic data on Thursday, as investors reviewed the latest corporate earnings news and digested remarks by Fed Chair. European stocks were down as mixed corporate results halted the rally that had propelled FTSE 100 and DAX to record highs. FTSE 100 was down 0.21% to 6935.38. Chinese stocks climbed to a four-week high amid speculation the nation will do more to support economic growth. China's HSBC/Markit Purchasing Managers' Index (PMI) inched up to 50.1 in February. Economists polled by Reuters had forecast a reading of 49.5, little changed from January's final PMI of 49.7. Japan's key Nikkei 225 index fell 0.1% and Australia's benchmark S&P ASX 200 index gained 0.3%.
Covance Inc. (Covance) reported that its stockholders voted to adopt the merger agreement, which was previously announced on November 3, 2014, providing for the acquisition of Covance by Laboratory Corporation of America Holdings (LabCorp) at a special meeting of Covance stockholders on February 18, 2015.
Intrexon Corporation (Intrexon) reported that it has entered into a definitive agreement to acquire ActoGeniX - a European clinical stage biopharmaceutical company building a new frontier in cellular therapeutics - the combination will bring new generation of orally delivered Biotherapeutics.
Quintiles Transnational Holdings Inc. (Quintiles Transnational) reported it is working with the National Football League (NFL) with an aim to track player injuries and understand trends in injury occurrence. The NFL recently signed a five-year agreement with Quintiles Transnational to continue and expand upon its Injury Surveillance and Analytics (ISA) service.
NanoViricides, Inc. (NanoViricides) reported that an optimized FluCide candidate was found to be safe in cGLP-like Safety and Toxicology Study in Rats Performed by Bioanalytical Systems, Inc. (BASi), indicating FluCide as the most promising among the advanced candidates in the Company's drug development pipeline.
Aradigm Corporation (Aradigm) announced that the European Patent Office has granted key composition of matter for Pulmaquin in Europe and Australia. The patent is entitled "Dual Action, Inhaled Formulations Providing Both an Immediate and Sustained Release Profile" (E.U. Patent No. 2,079,443), and has been issued to Aradigm for formulations of liposomal and free ciprofloxacin.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article